Moore Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Moore Capital Management's XBI Position: Q1 2026 in Review
Moore Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 225,000 shares — an estimated $27.4M sold.
Moore Capital Management first reported a position in XBI in Q4 2016 and held it in 15 quarters. The position peaked at $264M in Q4 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Moore Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
- Moore Capital Management sold 225,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $27.4M.
- Moore Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 15 quarters.
- Moore Capital Management's State Street SPDR S&P Biotech ETF position peaked at $264M in Q4 2022.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.